These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Blanken M; Rovers M; Sanders E; Bont L Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319 [TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants. Escobar GJ J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662 [No Abstract] [Full Text] [Related]
13. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up. Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146 [TBL] [Abstract][Full Text] [Related]
14. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Weisman LE Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726 [TBL] [Abstract][Full Text] [Related]
15. Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia. Shi X; Zheng J; Yan T J Mol Model; 2018 Mar; 24(4):79. PubMed ID: 29500665 [TBL] [Abstract][Full Text] [Related]
16. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season. Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351 [TBL] [Abstract][Full Text] [Related]
17. RSV immunoprophylaxis: does the benefit justify the cost? Meissner HC; Kimberlin DW Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478 [No Abstract] [Full Text] [Related]
19. Wheezing illness caused by respiratory syncytial virus and other agents. Yasuno T; Shimizu T; Maeda Y; Yamasaki A; Amaya E; Kawakatsu H Pediatr Int; 2008 Aug; 50(4):500-5. PubMed ID: 18937754 [TBL] [Abstract][Full Text] [Related]
20. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]